A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim ResultsChristopher A. Yasenchak, Andres Forero‐Torres, Jeff P. Sharman et al.|Blood|2013Cited by 5